Safety and Efficacy of Emixustat in Stargardt Disease

* A clinical diagnosis of macular atrophy secondary to Stargardt disease (STGD)

* Macular atrophy measured to fall within a defined size range

* Two mutations of the ABCA4 gene. If only one mutation, a typical STGD appearance of the retina.

* Visual acuity in the study eye of at least 20/320

* Macular atrophy secondary to a disease other than STGD

* Mutations of genes, other than ABCA4, that are associated with retinal degeneration

* Surgery in the study eye in the past 3 months

* Prior participation in a gene therapy or stem cell clinical trial for STGD

* Recent participation in a clinical trial for STGD evaluating a complement inhibitor or vitamin A derivative

* Use of certain medications in the past 4 weeks that might interfere with emixustat

* An abnormal electrocardiogram (ECG)

* Certain abnormalities on laboratory blood testing

* Female subjects who are pregnant or nursing